CXCR3 and bladder transitional cell carcinoma: In our study, by analyzing clinical, transcriptomic, and genomic data from the ICI and TCGA-BLCA cohorts, we found that mUC patients with higher CXCR3 pathway activation levels responded better to immunotherapy and had longer overall survival (OS) time than patients with lower CXCR3 pathway activation levels.